Now Available at Major U.S. Retailers
BRIDGEWATER, N.J., Oct. 21, 2019 /CNW/ -- Bausch + Lomb, a
leading global eye health company and wholly owned subsidiary of
Bausch Health Companies Inc. (NYSE/TXS: BHC), today announced
the U.S. launch of PreserVision® AREDS 2 Formula minigel eye
vitamins. The new minigels will replace the currently offered
PreserVision AREDS 2 Formula soft gels, offering patients an
easier-to-swallow option compared to the original AREDS 2 soft
gels. PreserVision® AREDS 2 Formula minigel eye vitamins contain
the exact nutrient formula recommended by the National Eye
Institute (NEI) for people with moderate to advanced Age-related
Macular Degeneration (AMD) following the landmark AREDS2 clinical
study.
"AMD is a leading cause of vision loss in Americans age 50 and
older. For my patients who are diagnosed with moderate to advanced
AMD, I typically recommend a plan that includes regular exercise, a
healthy diet, and PreserVision – a supplement that contains
nutrients recommended by the National Eye Institute to help reduce
the risk of AMD progression in these
patients," said Rishi Singh, M.D., Cole Eye Institute,
Cleveland Clinic. "I am pleased to recommend this new option
to my patients who have inquired about the availability of a
smaller sized PreserVision AREDS 2 formula
vitamin."1
It is estimated that as many as 16 million people in
the United States have AMD. In its
early stages, AMD may not present any symptoms, therefore patients
may not think to consult with their eye care professional—leaving
opportunity for the condition to advance. Left untreated, AMD has
the potential to lead to severe vision loss or blindness.
"Bausch + Lomb is committed to helping patients protect their
vision," said Joe Gordon, U.S.
president, Bausch + Lomb. "Patients who take or are considering
PreserVision AREDS 2 Formula minigel eye vitamins will now have a
new, easier-to-swallow1 option."
PreserVision AREDS 2 minigel eye vitamins are available at major
retailers nationwide in the vitamin aisle and have a suggested
retail price of $32.99 (120-count
bottle).
For more information on PreserVision eye vitamins, visit
www.preservision.com.
About Bausch + Lomb
Bausch + Lomb, a Bausch Health
Companies Inc. company, is a leading global eye health organization
that is solely focused on helping people see. Its core businesses
include over-the-counter products, dietary supplements, eye care
products, ophthalmic pharmaceuticals, contact lenses, lens care
products, ophthalmic surgical devices and instruments. Bausch +
Lomb develops, manufactures and markets one of the most
comprehensive product portfolios in the industry, which is
available in more than 100 countries. For more information, visit
www.bausch.com.
About Bausch Health
Bausch Health Companies Inc.
(NYSE/TSX: BHC) is a global company whose mission is to improve
people's lives with our health care products. We develop,
manufacture and market a range of pharmaceutical, medical device
and over-the-counter products, primarily in the therapeutic areas
of eye health, gastroenterology and dermatology. We are delivering
on our commitments as we build an innovative company dedicated to
advancing global health. More information can be found at
www.bauschhealth.com.
Forward-looking Statements
This news release may
contain forward-looking statements which may generally be
identified by the use of the words "anticipates," "expects,"
"intends," "plans," "should," "could," "would," "may," "will,"
"believes," "estimates," "potential," "target," or "continue" and
variations or similar expressions. These statements are based upon
the current expectations and beliefs of management and are subject
to certain risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. These risks and uncertainties include, but are not
limited to, risks and uncertainties discussed in Bausch Health's
most recent annual or quarterly report and detailed from time to
time in Bausch Health's other filings with the Securities and
Exchange Commission and the Canadian Securities Administrators,
which factors are incorporated herein by reference. Readers are
cautioned not to place undue reliance on any of these
forward-looking statements. These forward-looking statements speak
only as of the date hereof. Bausch Health undertakes no obligation
to update any of these forward-looking statements to reflect events
or circumstances after the date of this news release or to reflect
actual outcomes, unless required by
law.
PreserVision is a trademark of Bausch & Lomb Incorporated
or its affiliates.
AREDS2 is a registered trademark of
the United States Department of Health and Human Services
(HHS).
© 2019 Bausch & Lomb Incorporated or its
affiliates.
PVN.0093.USA.19
1 Compared to original PreserVision® AREDS 2
soft gels
Bausch Health
Investor:
|
Media
Contact:
|
Arthur
Shannon
|
Lainie
Keller
|
arthur.shannon@bauschhealth.com
|
lainie.keller@bauschhealth.com
|
(514)
856-3855
|
(908)
927-1198
|
(877) 281-6642 (toll
free)
|
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bausch--lomb-introduces-preservision-areds-2-formula-minigel-eye-vitamins-300941602.html
SOURCE Bausch Health Companies Inc.